Citi analyst Geoff Meacham initiated coverage of Vor Bio (VOR) with a Buy rating and $50 price target The firm believes the company is positioned to launch telitacicept to indications with “significant” unmet medical need, beginning with myasthenia gravis and Sjogren’s disease.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: